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Cardiovascular (CV) morbidity and mortality are increased in patients with active, untreated rheumatoid
arthritis (RA), despite lower levels of total and low-density lipoprotein cholesterol reported in individuals
with active RA compared with those without RA. Alterations in non-traditional lipid assessments, such as
high-density lipoprotein (HDL) function and HDL-associated proteins, have been described in patients
with active RA, including elevated HDL-associated serum amyloid A and decreased paraoxonase-1
activity. We review changes in both traditional lipoprotein concentrations and non-traditional lip-
oprotein assessments in multiple studies of treatment with disease-modifying antirheumatic drugs
(DMARDs), including non-biologic and biologic DMARDs and tofacitinib. In addition, data from a recently
published clinical trial with tofacitinib that describe a potential mechanism for suppression of cholesterol
levels in active RA patients are reviewed. Finally, CV event data from various studies of DMARDs are
presented, and the current management of RA patients with regard to the CV risk is reviewed.
& 2016 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
It is well known that cardiovascular (CV) morbidity and mortal-
ity are increased in patients with active, untreated rheumatoid
arthritis (RA). A recent meta-analysis [1] indicated that the risk of
CV events and mortality is approximately 50% higher in RA
patients compared with the general population. However, the
pathophysiological mechanisms linking CV disease (CVD) and RAr HS Journals, Inc. This is an open
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arles-Schoeman).are not completely understood. Traditional risk factors including
smoking, hypertension, dyslipidemia, and diabetes mellitus do not
alone explain the higher CV risk in patients with RA [2]. A genetic
component has been associated with the increased risk of CVD in
RA [3]. Inﬂammation, a key link between RA and CVD, which plays
an important role in all stages of atherosclerosis, also accentuates
some traditional CV risk factors, such as dyslipidemia [4]. It has
previously been observed that lipid levels change signiﬁcantly
during acute and chronic inﬂammatory illnesses, with an inverse
relationship between high-density lipoprotein cholesterol (HDL-C)
and C-reactive protein (CRP) [5].
In the general population, serum low-density lipoprotein cho-
lesterol (LDL-C) levels are strongly associated with an increased
risk of CVD [6,7]. HMG-CoA reductase inhibitors, or “statins”,
which lower LDL-C levels and have anti-inﬂammatory properties
[8,9], reduce the risks for coronary outcomes in both primary and
secondary prevention [10]. Low levels of HDL-C have also been
associated with increased CV risk in epidemiological studies [11];
however, emerging data, such as the poor performance of recent
clinical trials targeting elevation of HDL-C levels [12], suggest that
other factors are also involved. Increasingly, research is nowaccess article under the CC BY-NC-ND license
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than the levels of HDL-C alone [13].
In patients with RA, the relationship of LDL-C and HDL-C to CV
risk is even more complex, and our understanding of cholesterol
levels in the setting of active inﬂammation from RA has continued
to evolve. Myasoedova et al. [14] initially reported that, in the
5 years prior to diagnosis, patients with RA had signiﬁcant
decreases in total cholesterol (TC) and LDL-C levels over time
compared with a control population, despite lower rates of statin
use. These ﬁndings were consistent with studies showing lower
cholesterol levels in the setting of active inﬂammation from other
causes, including the post-surgical state, critical illness, and sepsis
[15–17]. Follow-up work in the same RA cohort of over 600
patients described a “lipid paradox”, in which lower TC and
LDL-C levels were not only associated with active inﬂammation
in RA patients, but also with higher rather than lower risk of CVD
[18]. This work further suggests signiﬁcant interactions between
systemic inﬂammation and cholesterol levels in the development
of CVD in RA.
Here we explore current thinking on the role of dyslipidemia as
a risk factor in RA. We also examine the impact of disease-
modifying antirheumatic drugs (DMARDs), including non-
biologic and biologic DMARDs and the oral Janus kinase (JAK)
inhibitor tofacitinib, on both traditional and non-traditional lipid
proﬁles in patients with RA. In particular, we will discuss recent
evidence for a potential mechanism of cholesterol kinetics, which
may in part explain the cholesterol changes associated with
inﬂammation in RA patients, and which is impacted by treatment
with DMARDs. In addition, we will present data on CV events in
patients with RA treated with DMARDs, including a number of
observational studies that have reported decreased CVD risk in RA
patients associated with treatment with various DMARDs [19–22].Methods
For data on the effects of DMARDs on lipid levels, PubMed was
searched using the name of the agent in question in combination
with terms such as “lipid,” “lipoprotein,” “cholesterol,” “cardiovas-
cular,” “paraoxonase,” and “rheumatoid arthritis”. Further relevant
information was identiﬁed from the reference lists of articles
returned using these search terms and from authors0 own expe-
rience and knowledge of the literature.Results
Effects of DMARDs on traditional lipid proﬁles
Non-biologic DMARDs
A relationship between changes in lipid levels and disease
activity was ﬁrst observed with non-biologic DMARDs. In the
Dutch Combinatietherapie Bij Reumatoide Artritis (Combination
Therapy in Early RA; COBRA) study, in which 134 newly diagnosed
RA patients received either sulphasalazine as monotherapy or in
combination with MTX and prednisolone, both groups showed
signiﬁcant increases in cholesterol levels from baseline, with
signiﬁcantly greater increases in TC and HDL-C at Week 16 in the
combination group, which also had greater improvement in
disease activity [23].
In another study by Georgiadis et al. [24], lipid proﬁles were
evaluated in 58 DMARD-naïve, early-RA patients who were treated
with MTX and prednisolone. Signiﬁcant increases from baseline in
TC and HDL-C levels, and signiﬁcant decreases in the TC/HDL-C
ratio, occurred after 1 year of therapy. The increases in TC andHDL-C were inversely correlated with the reduction in both ESR
and CRP values [24].
Finally, the use of hydroxychloroquine (HCQ) in RA has been
associated with improvement in lipid proﬁles in RA patients.
Speciﬁcally, in an observational study of 706 RA patients, HCQ
use was independently associated with a signiﬁcant decrease in
TC, LDL-C, and the TC/HDL-C ratio [25].
Biologic DMARDs
Tocilizumab. Interest in the impact of DMARDs on lipids and CV
risk has largely been driven by the lipid changes observed in
clinical trials of tocilizumab (TCZ), a humanized monoclonal
antibody against the interleukin-6 receptor.
In a study of active controlled RA monotherapy (SAMURAI
study), 306 patients with active RA of o5 years duration were
randomized to receive TCZ monotherapy at 8 mg/kg intravenously
every 4 weeks or non-biologic DMARDs for 52 weeks [26]. No
change in the TC/HDL-C ratio was observed during the study,
although increases in TC, LDL-C, and triglycerides (TG) were
observed in 38%, 26%, and 17% of patients, respectively. HDL-C
levels were elevated above the normal range with TCZ treatment
in 24% of patients [26]. Smolen et al. [27] have described a double-
blind, randomized, placebo-controlled Phase 3 trial of TCZ
(OPTION study) involving 623 patients with moderate-to-severe
active RA despite MTX treatment. In this study, increases 430%
above baseline in TC/HDL-C ratios occurred in 8% and 17% of
patients administered 4 mg/kg and 8 mg/kg TCZ, respectively.
A similar level of effects on lipid proﬁles has been noted in other
studies of TCZ [28–34].
In light of these observations, a further double-blind, placebo-
controlled Phase 3 trial (MEASURE) was conducted to assess the
impact of TCZ on lipid and lipoprotein levels, as well as markers of
coagulation, thrombosis, and vascular function [35]. In this study,
median TC and LDL-C increased in TCZ versus placebo recipients by
Week 12.
TNF inhibitors. A meta-analysis of 15 studies in over 700 patients
found increases in TC (to a maximum of 10% above baseline) and
HDL-C (to a maximum of 7% above baseline) within 6 months of
starting TNFi treatment [36]. In another meta-analysis that
included 13 prospective studies, 6–12 months of TNFi treatment
in 338 patients was associated with increased levels of HDL-C,
whereas LDL-C levels and the atherogenic index did not change
signiﬁcantly after treatment [37].
Effects of the newer TNFi treatment golimumab on lipids in two
randomized controlled trials in patients with RA — GO-BEFORE
(n ¼ 637, MTX-naïve) and GO-FORWARD (n ¼ 444, MTX-
inadequate responders) — have been reported [38]. Patients were
randomized to receive placebo þ MTX, golimumab 100 mg þ
placebo, golimumab 50 mg þ MTX, or golimumab 100 mg þ MTX.
In GO-FORWARD, TC, LDL-C, and HDL-C levels were increased in all
treatment groups at Week 14 and were greater in the golimumab
þ MTX groups than in the placebo þ MTX group. In GO-BEFORE,
TC and LDL-C levels increased from baseline to Week 24 in all
treatment groups, without any signiﬁcant differences between the
placebo þ MTX and the golimumab þ MTX groups [38].
The relationship between cholesterol changes and treatment
response has also been studied in RA patients receiving TNFi
treatment. In the Etanercept Treatment in RA (ETRA) observational
cohort study, which followed 292 patients with RA treated with
etanercept over 1 year, signiﬁcant changes in apolipoprotein A-I
(apoA-I; increased from baseline by 3.5% [p ¼ 0.002] at 4 months
and 3.1% [p ¼ 0.005] at 1 year) and apolipoprotein B (apoB)/apoA-I
ratio (decreased from baseline by 6.2% [p o 0.001] at 4 months
and 3.6% [p ¼ 0.025] at 1 year) were observed in patients who
achieved European League Against Rheumatism (EULAR) response
C. Charles-Schoeman et al. / Seminars in Arthritis and Rheumatism 46 (2016) 71–80 73criteria; no signiﬁcant differences were observed at any time point
in patients who did not achieve the EULAR response criteria [39].Tofacitinib
In Phases 2 and 3 studies of tofacitinib 5 mg or 10 mg twice
daily (BID) administered either as monotherapy or with back-
ground non-biologic DMARDs, mean increases in LDL-C and HDL-C
were generally between 10% and 20%, with most increases occur-
ring during the ﬁrst 4 weeks of treatment and stabilizing after
3 months of treatment [40–48]. These increases were similar in
the monotherapy and background DMARD studies.
A pooled analysis was conducted using data from ﬁve Phase 3
trials of tofacitinib in patients with an inadequate response to
DMARDs, one trial as monotherapy (NCT00814307) [47], and four
with background non-biologic DMARDs (NCT00847613;
NCT00960440; NCT00856544; and NCT00853385) [43–46]. This
analysis corroborated the individual trial results, demonstrating
dose-dependent increases in serum TC, LDL-C (Fig. 1a), and HDL-C
(Fig. 1b), with changes observed within 1–3 months of the start of
tofacitinib therapy and showing stable levels thereafter [49]. In the
tofacitinib 10 mg BID group, LDL-C increased by approximately
20% and HDL-C increased by approximately 15–20% from baseline.
In the tofacitinib 5 mg BID group, both LDL-C and HDL-C increasedFig. 1. Mean (7 SE) percentage change from baseline in (A) LDL-C and (B) HDL-C in ﬁve
patients on tofacitinib monotherapy as well as those receiving concomitant backgroundby approximately 15% from baseline. These increases were similar
irrespective of whether patients received tofacitinib as monother-
apy or together with non-biologic DMARDs. Importantly, given
evidence suggesting that both TC/HDL-C and LDL-C/HDL-C ratios
are predictors of CV risk [50,51], little change was seen in the
LDL-C/HDL-C ratio in either dose group [49].
Additional analyses have been performed to better characterize
the impact of tofacitinib on lipid proﬁles. LDL-C data from 1474
patients participating in ﬁve double-blind, Phase 2 trials, and two
open-label long-term extension (LTE) studies, were pooled and
analyzed using a longitudinal, non-linear mixed-effects model
[52]. Patients achieving an American College of Rheumatology
50% response (ACR50) showed a modestly greater maximal LDL-C
increase compared with non-responders [52]. Consistent with trial
results, mean maximal LDL-C increases were predicted to be
reached by 5 weeks. There was no evidence of a progressive
increase for treatment durations of up to 3 years in LTE studies
(Fig. 2). An additional analysis of pooled Phase 3 tofacitinib data
[43–47] investigated the relationship between laboratory param-
eters, including LDL-C and HDL-C, and CRP, and showed that the
greatest mean changes from baseline in LDL-C and HDL-C were
observed in those patients with the greatest reductions in CRP
[53]. The relationship between the increases in LDL-C and HDL-C
and the reduction in CRP were approximately linear [53].Phase 3 studies of tofacitinib over 0–12 months of treatment (data shown include
DMARDs).
Fig. 2. Comparison of LDL-C levels in Phase 2 and long-term extension studies of tofacitinib 5 mg BID at different time points.
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tofacitinib-associated elevations in TC, LDL-C, TG, and apoB. In this
study, patients with RA receiving open-label treatment with
tofacitinib 10 mg BID were randomized (after 6 weeks of tofaciti-
nib treatment) to receive, in addition, double-blind atorvastatin
10 mg once daily (n¼50) or placebo (n ¼ 48) for a further 6 weeks
[54]. The addition of atorvastatin signiﬁcantly reduced tofacitinib-
associated increases in TC, LDL-C, TG, and apoB to below baseline
levels (Fig. 3) [54].
Comparison of lipid changes between DMARDs
A recent meta-analysis of randomized controlled trials found
that tofacitinib, TCZ, and TNFi treatment were all associated with
moderate changes in lipids (including higher levels of LDL-C and
HDL-C) in patients with RA [55]. Additional studies have also
shown, however, that lipid levels vary signiﬁcantly depending on
the RA patient population and response to therapy, as well as the
speciﬁc treatment received.
In the Treatment of Early Rheumatoid Arthritis (TEAR) trial,
DMARD-naïve patients with early RA were randomized to receive
treatment with MTX monotherapy, MTX and etanercept combina-
tion therapy, or triple oral therapy (MTX þ sulphasalazine þ
HCQ). After 6 months, lipid levels were assessed in 459
patients and signiﬁcant increases from baseline in mean TC
(53–57.3 mg/dL), LDL-C (28.7–31.4 mg/dL), and HDL-C (19.3–22.3
mg/dL) were noted, with no differences between treatment arms.
TC/HDL-C ratios decreased slightly in all treatment arms and CRP
levels were signiﬁcantly and negatively associated with TC and
LDL-C levels [56].
Potential mechanism for changes in traditional lipid proﬁles in
patients with active RA and following treatment with tofacitinib
Cholesterol ﬂux through the HDL/reverse cholesterol transport
pathway involves the transport of free cholesterol (FC) from
peripheral tissues via transporter-dependent and -independent
mechanisms to the HDL particle. Once part of the HDL particle,FC can be esteriﬁed to cholesterol ester (CE) by lecithin–choles-
terol acyltransferase (LCAT). CEs may then be transferred from HDL
to LDL via CE transfer proteins (CETP). CEs are delivered to the
liver for secretion in bile and ultimately excretion in the stool
(Fig. 4) [57].
In order to better understand the mechanisms behind suppres-
sion of cholesterol levels in patients with active systemic inﬂam-
mation as well as the changes in lipids observed during RA
treatment, a novel in vivo model of cholesterol and lipoprotein
kinetics was used [58]. In a small Phase 1 mechanism-of-action
trial, 36 patients with RA and 33 matched healthy volunteers
received [13C] cholesterol and [13C] leucine infusions. A multi-
compartment model was used to determine the CE fractional
catabolic rate (CE FCR), CE production rate, and total cholesterol
efﬂux rate.
The CE FCR was greater in patients with active RA compared
with healthy volunteers; however, no differences in CE production
rate, CETP, or HDL-apoA-I and LDL-apoB FCR were observed
(Table 1). Following tofacitinib treatment in patients with RA, the
CE FCR decreased (p ¼ 0.0014 versus baseline) and cholesterol
levels increased (Table 1). A signiﬁcant inverse correlation was
noted between the change in CE catabolism and the change in
HDL-C. Greater decreases in CE catabolism with tofacitinib treat-
ment were associated with greater increases in HDL-C. These data
suggest that lower cholesterol levels in patients with active RA
may be driven in part by increases in CE catabolism, which are
reversed by tofacitinib [57]. Results of this study are discussed in
detail elsewhere [57].
Changes in non-traditional lipid parameters and the effects of
DMARDs in RA patients: lipoprotein function and structure
Changes in non-traditional lipid parameters in RA patients
Accumulating data in both the general population as well as RA
patients suggest that alterations in the composition and function
of lipoproteins may be particularly important additional determi-
nants of CV risk [1]. RA patients with active disease and high levels
Fig. 3. Mean LDL-C, total cholesterol, triglyceride, apoA-I, and apoB levels over time with atorvastatin þ tofacitinib and placebo þ tofacitinib [54]. Reproduced fromMcInnes
et al. [54] with permission from BMJ Publishing Group Ltd.
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related morbidity and mortality [3]. These patients have circulat-
ing HDL that is impaired in its ability to prevent oxidation of LDL,
and may even promote rather than prevent LDL oxidation (pro-
inﬂammatory HDL) [59]. Previous proteomic analysis of HDL from
RA patients with active disease and pro-inﬂammatory HDL has
demonstrated signiﬁcant differences in multiple HDL-associated
proteins — including acute-phase proteins such as serum amyloid
A (SAA) and haptoglobin, as well as several other proteins such as
those involved in the complement cascade — when compared
with HDL from patients with quiescent RA and anti-inﬂam-
matory HDL [60].
Active RA has also been associated with impairment in the
ability of HDL to promote cholesterol efﬂux from peripheral cells.
Initial work in a small number of RA patients showed that HDL
from RA patients with high disease activity, measured by a Disease
Activity Score (DAS) with 28 joint-count (DAS28) 45.1, had
signiﬁcantly decreased ability to promote cholesterol efﬂux com-
pared with HDL from patients with very low disease activity(DAS28 o 2.6). Correlations were noted between the cholesterol
efﬂux capacity of HDL (the capacity of HDL to accept cholesterol
from macrophages) and the DAS28 score (r ¼ 0.39, p ¼ 0.01), as
well as inﬂammation measured by the erythrocyte sedimentation
rate (r ¼ 0.41, p ¼ 0.0009) [61].
Vivekanandan-Giri et al. [62] also studied the cholesterol efﬂux
capacity of HDL and showed that HDL derived from RA patients
had diminished efﬂux capacity compared with HDL derived from
healthy volunteers. Levels of myeloperoxidase (MPO), a heme
peroxidase abundant in activated neutrophils that can oxidatively
modify HDL, were higher in the RA patients compared with
healthy subjects. There was also a marked increase in MPO-
speciﬁc 3-chlorotyrosine and 3-nitrotyrosine content in HDL in
the RA subjects, which was consistent with speciﬁc oxidative
modiﬁcation of HDL by MPO. The efﬂux capacity of HDL correlated
inversely with the 3-chlorotyrosine content [62].
Serum paraoxonase-1 (PON-1) is an HDL-associated enzyme,
which is synthesized and secreted by the liver. PON-1 reduces the
oxidizing potency of lipids in atherosclerotic lesions, providing
Fig. 4. Reverse cholesterol transport [57]. Reproduced from Charles-Schoeman et al. [57] with permission from John Wiley & Sons Inc.
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shown to be associated with an increased risk of CV events [63,64].
Relationships between PON-1 activity, PON-1 genotype (for the
functional polymorphism at position 192), and carotid plaque
presence were determined in 168 RA patients [65]. Patients with
the RR genotype (higher PON-1 activity) demonstrated decreased
risk of carotid plaque on multivariate analysis, controlling forTable 1
Summary of lipid parameters and kinetics in patients with RA before and after treatme
RA patients
Mean (standard deviation) Baseline
Lipid and lipoprotein concentrations (n ¼ 36)
Total cholesterol (mmol/L) 5.02 (0.84)**
LDL-cholesterol (mmol/L) 3.23 (0.74)**
HDL-cholesterol (mmol/L) 1.41 (0.32)**
ApoB (g/L) 0.81 (0.42)
ApoA-1 (g/L) 1.17 (0.56)**
Cholesterol and lipoprotein kinetics (n ¼ 32)
LDL-ApoB FCR (%/h) 1.61 (0.37)
LDL-ApoB production rate (mg/kg/h) 0.49 (0.12)
HDL-ApoA-1 FCR (%/h) 1.08 (0.22)
HDL-ApoA-1 production rate (mg/kg/h) 0.57 (0.11)
HDL dysfunction (n ¼ 36)
HDL-SAA (mg/L) 34.76 (62.83)**
SAA (mg/L) 51.93 (95.61)**
Myeloperoxidase (pmol/L) 1092.00 (1017.05)**
LCAT mass (mg/L) 8200 (2020)**
LCAT activity (nmol/mL/h) 596.03 (138.58)**
CETP activity (pmol/mL/min) 60.41 (8.87)
CETP mass (μg/L) 1960 (520)
Particle size (n ¼ 36)
Total HDL particles (mmol/L) 30.66 (4.80)**
HDL size (nm) 9.10 (0.40)
Total LDL particles (nmol/L) 1276.19 (391.50)
LDL size (nm) 21.01 (0.85)
Apo, apoliprotein; BID, twice daily; CETP, CE transfer protein; FCR, fractional catabolic r
low-density lipoprotein; RA, rheumatoid arthritis; SAA, serum amyloid A.
n p o 0.05 versus baseline for patients with RA.
nn p o 0.05 paired difference versus healthy volunteers.
† Tofacitinib 10 mg BID for 6 weeks.traditional CV risk factors, high-sensitivity CRP levels, and use of
prednisone and cholesterol-lowering medication (p o 0.05).
Lower plasma PON-1 activity was associated with increased risk
of carotid plaque. A recent study in a cohort of 585 Spanish
patients with RA did not support the association of subclinical
atherosclerosis with the PON-1 rs662 polymorphism [66], suggest-
ing that further CV outcome studies are warranted.nt with tofacitinib, and in healthy volunteers [57].
Tofacitinib-treated† Baseline healthy volunteers
(n ¼ 36) (n ¼ 31)
5.69 (1.07)* 5.74 (1.09)
3.70 (1.01)* 3.75 (0.94)
1.61 (0.39)* 1.64 (0.44)
0.93 (0.42)* 0.82 (0.48)
1.35 (0.58)* 1.28 (0.68)
(n ¼ 32) (n ¼ 30)
1.57 (0.41) 1.50 (0.35)
0.52 (0.12) 0.50 (0.13)
1.11 (0.28) 1.02 (0.22)
0.65 (0.15)* 0.59 (0.16)
(n ¼ 36) (n ¼ 31)
17.79 (34.45) 2.98 (2.33)
24.97 (48.96) 3.47 (2.71)
942.86 (942.64) 736.39 (344.79)
8980 (2320)* 9810 (1540)
642.47 (133.57)* 687.81 (120.52)
58.87 (7.25) 58.25 (6.58)
1970 (450) 1920 (570)
(n ¼ 36) (n ¼ 31)
33.85 (5.51)* 35.00 (5.92)
9.09 (0.51) 9.20 (0.39)
1352.67 (498.79) 1357.87 (540.11)
21.20 (0.97)* 21.36 (0.89)
ate; HDL, high-density lipoprotein; LCAT, lecithin–cholesterol acyltransferase; LDL,
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Biologic DMARDs. In a study by Popa et al. [67], investigating the
impact of 6 months of inﬂiximab therapy on plasma lipids and
PON-1 activity in 45 patients with RA, plasma HDL-C levels did not
exhibit any signiﬁcant changes, but stable increases in PON-1
activity were observed (p o 0.03) and the total antioxidative
capacity of HDL-C signiﬁcantly improved (p ¼ 0.015) [67].
Tocilizumab. In the Phase 3 MEASURE trial of 132 patients who
received treatment with TCZ 8 mg/kg þ MTX or placebo þ MTX,
HDL-SAA was signiﬁcantly reduced (by 78%) versus baseline in the
TCZ þ MTX arm at Week 12 [35]. In contrast, PON-1 was signiﬁcantly
increased (by 16%) in TCZ-treated patients. These observations
suggest a remodeling of HDL-C particles from a pro-inﬂammatory
to an anti-inﬂammatory phenotype in response to TCZ treatment [35].
TNF inhibitors. In the GO-FORWARD trial in MTX-inadequate
responders, atherogenic ratios, including TC/HDL-C and apoB/
apoA-I, were generally stable in all treatment groups, but
patients treated with golimumab þ MTX had signiﬁcantly greater
median decreases in serum SAA concentrations compared with
patients receiving placebo þ MTX at Week 14. In the GO-BEFORE
trial in an MTX-naïve population, total small, very small, and
medium small LDL-C levels decreased in all treatment groups,
without any signiﬁcant differences between groups. At Week 24,
decreases in SAA were signiﬁcantly greater in the combined
golimumab þ MTX groups than in the placebo þ MTX group [38].
In the double-blind TEAR study comparing lipid changes
between DMARDs, levels of HDL-SAA were lower by an average
of 66 ranks following treatment with MTX plus etanercept
compared with triple oral therapy [68].
Tofacitinib. Exploratory analyses of protein biomarkers related to
HDL-C function were performed in the Phase 1 study of tofacitinib
described above and in Table 1, and patients with RA were found to
have higher levels of HDL-associated SAA (HDL-SAA), SAA, and MPO,
and lower activity and mass of LCAT — an HDL-associated enzyme
integral to efﬂux capacity compared with healthy volunteers at
baseline (Table 1) [57]. Higher MPO activity and HDL-SAA have
previously been associated with dysfunctional HDL in both RA and
non-RA patients [59]. After tofacitinib treatment, LCAT mass and
activity were signiﬁcantly increased, and total and HDL-SAA wereTable 2
Summary of mean change from baseline at Month 3 in lipid biomarkers in patients tr
Phase 3 trial [69]. Reproduced from McInnes et al. [69] with permission from BMJ Publ
Pooled Phase 2/Phase 3 studies
Mean (standard error) Tofacitinib (5 mg BID) Tofacitinib (10 mg BID) Pl
Total SAA (mg/L) 54.99 (8.03)* [n ¼ 94] 42.69 (7.81)* [n ¼ 95]
HDL-associated SAA (mg/L) 30.79 (6.36)* [n ¼ 85] 34.44 (6.33)* [n ¼ 83]
LCAT (nmol/mL/h) 40.29 (12.27)* [n ¼ 99] 27.43 (12.70)* [n ¼ 89] 
Lp(a) (mg/dL) 1.51 (0.85) [n ¼ 101] 1.58 (0.90) [n ¼ 89]
PON-1 (U/L) 3.34 (0.76)* [n ¼ 166] 3.62 (0.77)* [n ¼ 157]
CETP (pmol/mL/min) 1.98 (0.64) [n ¼ 62] 0.38 (0.64) [n ¼ 63]
Lp-PLA2 17.90 (12.50) [n ¼ 101] 27.83 (12.85) [n ¼ 92] 
BID, twice daily; CETP, cholesteryl ester transfer protein; CV, cardiovascular; HDL, high-d
Lp-PLA2, lipoprotein-associated phospholipase A2; PON-1, paraoxonase-1; SAA, serum a
n p o 0.05 versus placebo.decreased (Table 1). In additional exploratory analyses, small but
potentially favorable effects on lipoprotein particle size and number
were observed with tofacitinib treatment. Speciﬁcally, the total
HDL-C particle number was decreased in patients with RA
compared with healthy volunteers at baseline, and increased in
RA patients after treatment with tofacitinib. LDL-C particle size also
increased slightly following treatment with tofacitinib (Table 1) [57].
An additional exploration of biomarkers relevant to lipid bio-
chemistry and CV risk has been performed on pooled data from
two Phase 2 and one Phase 3 study of tofacitinib versus placebo in
patients with RA [69]. Compared with placebo, tofacitinib 5 mg BID
or 10 mg BID signiﬁcantly increased activity of LCAT and PON-1
at Month 3 versus baseline (Table 2). Decreases in total and
HDL-SAA were observed with tofacitinib versus placebo, but no
signiﬁcant changes in CETP activity, or levels of lipoprotein(a) or
lipoprotein-PLA2, occurred (Table 2) [69].
Correlations are starting to emerge between reductions in RA
inﬂammation and increases in lipid levels and changes in lip-
oprotein composition with some DMARDs such as tofacitinib, but
further work is needed to fully understand the mechanisms
behind these relationships. It remains unclear if or how tofacitinib
inhibition of the JAK pathway and signaling by pro-inﬂammatory
cytokines can inﬂuence lipid structure and function. The similar-
ities in the changes in lipid proﬁles observed in association with
tofacitinib and TCZ treatment [70] suggest that interleukin-6 or its
inhibition may affect lipid levels, but this remains speculative.
CV events and the impact of DMARDs
The apparently paradoxical reduction in cholesterol levels and
elevated CV risk in patients with active RA highlights our current
lack of knowledge about the role of lipids in CV risk in RA patients.
It is becoming increasingly clear that traditional scoring systems
for CV risk in the general population do not accurately predict CV
risk for patients with RA [71,72]. Non-invasive surrogate markers
of atherosclerosis, such as carotid ultrasound, can improve CV risk
stratiﬁcation in patients with RA [73–75], enabling patients who
were previously wrongly categorized as immediate risk with
classic chart scores to be identiﬁed as high or very high risk, and
be treated appropriately to minimize risk.
A number of studies have reported a reduction in CV risk
associated with both biologic and non-biologic DMARDs, despiteeated with tofacitinib or placebo in a pooled analysis from two Phase 2 and one
ishing Group Ltd.
acebo Interpretation
13.40 (9.31) [n ¼ 66] ⇩ with tofacitinib 5 and 10 mg BID
Decrease suggests improved function of HDL9.46 (7.32) [n ¼ 62]
24.32 (15.57) [n ¼ 59] ⇧ with tofacitinib 5 and 10 mg BID
Increased activity would promote reverse cholesterol
transport
0.97 (1.02) [n ¼ 68] No signiﬁcant change with tofacitinib 5 and 10 mg BID
Increases associated with CV risk
0.29 (0.92) [n ¼ 97] ⇧ with tofacitinib 5 and 10 mg BID
Increase may indicate improved function of the HDL
particle
0.37 (0.77) [n ¼ 45] No signiﬁcant change with tofacitinib 5 and 10 mg BID
Reductions associated with CV beneﬁt
1.76 (14.65) [n ¼ 70] No change with tofacitinib 5 and 10 mg BID
Reduced levels associated with reduced
inﬂammation and atherosclerotic progression
ensity lipoprotein; LCAT, lecithin-cholesterol acyltransferase; Lp(a), lipoprotein (a);
myloid A.
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above. In a 10-year observational cohort study of 741 patients with
RA, decreased CVD risk was associated with use of any biologic or
non-biologic DMARD and MTX during the ﬁrst year following
diagnosis, or regular use of MTX after the ﬁrst year [19]. A
signiﬁcantly lower overall rate of serious cardiac events was seen
in etanercept-treated patients (1.0 per 100 person-years) com-
pared with those receiving non-biologic DMARDs (1.8 per 100
person-years) in a UK observational study of 3529 RA patients [20].
A recent meta-analysis that included 28 studies in RA has shown
TNFi treatment to be signiﬁcantly associated with a reduction in
the risk of all CV events [21]. Analysis of data from 14,878 RA
patients in Finland showed that patients with recent-onset RA
who receive consistent RA medication had no increased risk for CV
mortality compared with the general population over the duration
of the study, and that treatment with MTX was associated with
reduced CV mortality [76].
Accumulating evidence indicates that treatment with a TNFi
may lower CV risk. Data from 10,156 patients enrolled in the large
Consortium of Rheumatology Researchers of North America (COR-
RONA) RA registry showed that, after adjusting for age, gender, CV
risk factors and RA disease characteristics, patients using a TNFi
experienced a reduced risk of CV events (hazard ratio ¼ 0.39,
95% CI: 0.19–0.82) compared with users of non-biologic DMARDs [22].
A prospective cohort study in Canada found that RA patients
receiving biologic DMARDs (adalimumab, abatacept, TCZ, and
etanercept or rituximab) experienced a 12% reduction in risk of
cardiac events over 2 years, with TCZ (p ¼ 0.002) and abatacept
(p ¼ 0.042) associated with the greatest reduction in CV risk [77].
Analysis of pooled data from TCZ-treated RA patients found
that changes in lipid parameters were not statistically signiﬁcantly
associated with risk for on-treatment major adverse CV events
(MACE; CV death, non-fatal myocardial infarction, and non-fatal
cerebrovascular events) [78], despite increases in TC, LDL-C, and
TC/HDL-C ratio observed with TCZ treatment. A postmarketing
surveillance study of TCZ-treated RA patients in Japan showed no
increase in serious cardiac dysfunction in 4527 patients complet-
ing 3 years of follow-up [79]. However, more data are needed to
fully characterize the CV risk presented by TCZ. The ENTRACTE trial
(NCT01331837) is currently ongoing and compares the effects of
TCZ and etanercept on CV outcomes in patients with RA and at
least one CV risk factor.
To date, studies conducted with tofacitinib show no increase in
MACE despite elevated lipid levels, although more data from
ongoing long-term studies are needed to further assess any
possible link between CV events and treatment with tofacitinib.
In a pooled analysis of data from ﬁve Phase 3 trials [43–47], the
incidence rate for MACE was similar for tofacitinib and placebo
[0.57 (95% CI: 0.33–1.01) versus 0.99 [95% CI: 0.25–3.95] events per
100 patient-years, including 3030 patients exposed for 2098
patient-years] [80]. The incidence rates for MACE in the tofacitinib
and placebo groups in the Phase 3 populations corresponded to a
10-year Framingham CV risk of 6–10%, which is categorized as low
in the general population [49].
A lower incidence rate for MACE compared with the Phase 3
pooled analysis was seen in a pooled analysis of two open-label
LTE tofacitinib studies [0.19 (95% CI: 0.09–0.46) events per 100
patient-years; including 3227 patients with 2622 patient-years of
exposure, data cut-off date March 2011] [80]. In a later pooled
analysis from these two LTE trials (data cut-off date April 2013),
the incidence rate for MACE with tofacitinib was still below that
reported in the Phase 3 trials [0.37 (95% CI: 0.26–0.52) events per
100 patient-years, including 4827 patients with 8699 patient-
years of exposure] [81]. However, the characterization of the
risk/beneﬁt proﬁle of tofacitinib in LTE studies is potentially
limited due to the selection of patients who completed precedingindex studies, remained enrolled in the LTE studies, and in whom
tofacitinib was efﬁcacious and well tolerated. As such, no deﬁnitive
conclusions can currently be reached on the potential CV risk
presented by tofacitinib for RA and larger, longer-term studies are
required. An ongoing Phase 3b/4 study (NCT02092467) will
compare the safety of tofacitinib versus TNFi, particularly with
respect to MACE and malignancies.Conclusions and future directions
RA is associated with a high CV morbidity and mortality, and as
our knowledge of the relationship between lipid levels, lipoprotein
function, and CV risk continues to evolve, it is important to follow
currently available guidelines and monitor traditional lipid pro-
ﬁles. Previous data suggest there may be underdiagnosis and
undertreatment of dyslipidemia in patients with RA. In a recent
population-based cohort study, rates of lipid testing were lower in
patients with RA than in the general population and only around a
quarter of RA and non-RA subjects who met National Cholesterol
Education Program Adult Treatment Panel III criteria for lipid-
lowering therapy received it within 2 years of meeting the guide-
lines for initiation [82]. Further to such ﬁndings described in this
paper, it is recommended that assessment of lipid parameters
should be performed approximately 4–8 weeks after initiation of
tofacitinib therapy [83].
There are currently no deﬁnitive guidelines for statin use in RA
patients, and the Trial of Atorvastatin for the primary prevention of
Cardiovascular Events in patients with Rheumatoid Arthritis
(TRACE RA) (controlled-trials.com; ISRCTN41829447) was termi-
nated early with low numbers of CV events. However, these agents
continue to be widely used in the RA population. A population-
based longitudinal study of RA patients with incident statin use
followed from 1996 to 2006 showed that statin discontinuation in
patients with RA is associated with an increased risk of death from
CVD and all causes, supporting the importance of compliance in
RA patients who are prescribed statins [84].
Additional CV outcome studies with RA therapies are necessary
to further evaluate non-traditional lipid measurements such as
lipoprotein function, particle size, and number in relation to CV
risk in RA. Future studies should also explore the correlation of
treatment-related resolution of inﬂammation, changes in lipid
levels and other risk factors with CVD outcomes in RA [70].
We anticipate that in the future, the CV risk proﬁle of RA therapies
may be a key component of treatment selection with ongoing
monitoring of lipid levels and lipoprotein function and structure
becoming the standard of care.Acknowledgments
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